77 related articles for article (PubMed ID: 16286739)
1. Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures.
Hofbauer GF; Hatta N; Daigle I; Hemmi S; Spanaus Schlapbach K; Willers J; Burg G; Simon HU; Dummer R
Dermatology; 2005; 211(4):318-24. PubMed ID: 16286739
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
Song JH; Song DK; Herlyn M; Petruk KC; Hao C
Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
[TBL] [Abstract][Full Text] [Related]
4. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
Thomas WD; Hersey P
J Immunol; 1998 Sep; 161(5):2195-200. PubMed ID: 9725211
[TBL] [Abstract][Full Text] [Related]
5. FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death.
Lawrence CP; Chow SC
FEBS Lett; 2005 Nov; 579(28):6465-72. PubMed ID: 16289096
[TBL] [Abstract][Full Text] [Related]
6. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
Martin JH; Potthoff A; Ledig S; Cornberg M; Jandl O; Manns MP; Kubicka S; Flemming P; Athmann C; Beil W; Wagner S
Helicobacter; 2004 Oct; 9(5):371-86. PubMed ID: 15361075
[TBL] [Abstract][Full Text] [Related]
7. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
8. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack.
Martínez-Lorenzo MJ; Anel A; Alava MA; Piñeiro A; Naval J; Lasierra P; Larrad L
Exp Cell Res; 2004 May; 295(2):315-29. PubMed ID: 15093732
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
10. Human mast cells induce caspase-independent DNA fragmentation in leukemic T cells.
Gallagher SJ; Marshall JS; Hoskin DW
Oncol Rep; 2003; 10(4):1019-23. PubMed ID: 12792763
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
13. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures.
Kabsch K; Mossadegh N; Kohl A; Komposch G; Schenkel J; Alonso A; Tomakidi P
Intervirology; 2004; 47(1):48-56. PubMed ID: 15044836
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
15. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis of bovine ovarian surface epithelial cells by Fas antigen/Fas ligand signaling.
Margalit KA; Cowan RG; Harman RM; Quirk SM
Reproduction; 2005 Nov; 130(5):751-8. PubMed ID: 16264104
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma.
Choi C; Park JY; Lee J; Lim JH; Shin EC; Ahn YS; Kim CH; Kim SJ; Kim JD; Choi IS; Choi IH
J Immunol; 1999 Feb; 162(4):1889-95. PubMed ID: 9973455
[TBL] [Abstract][Full Text] [Related]
18. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
20. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
